Background: Psoriasis vulgaris (PsV) is a chronic skin condition that has a major impact on health-related quality of life (HRQOL).
Aim: To determine the individual burden of PsV on HRQOL using willingness to pay (WTP) instrument.
Materials and methods: Fifty-one consecutive PsV patients were asked to evaluate their overall health and psoriasis affected health by visual analogue scale (VAS), and interviewed on 8 domains (physical, emotional, sleep, work, social, self-care, intimacy, and concentration) of HRQOL and WTP for a hypothetical cure in each domain. Two additional questions proposing 6 alternatives for therapy were also asked. The analysis is performed with descriptive and frequency statistics, Mann-Whitney and Kruskal-Wallis tests.
Results: The domains ranked highly were: physical comfort (90%), social comfort (77%), emotional health (75%) and work (53%). The following tendencies concerning WTP for top four impacted domains were found: the median WTP were the highest in the top impacted domains; the younger patients were willing to pay more than the older ones; the highest median WTP amounts appear in the lowest income group; the highest median WTP is associated with smaller psoriasis affected health VAS scores. The largest proportion and number of patients (37.3%, n=19) stated preferences for the systemic therapy. The second preferred choice was the thalassotherapy (29.4%, n=15).
Conclusions: The utility and reliability of the instrument based on the assessment of WTP stated preferences for 8 domains of HRQOL for evaluation the individual burden of psoriasis were strongly supported.
1. Menter A, Stoff B. Psoriasis. London, UK: Manson Publishing Ltd; 2010.
2. Sarkar R, Chugh S, Bansal S. General measures and quality of life issues in psoriasis. Indian Dermatol Online J 2016;7(6):481-8.
3. Bhosle M, Kulkarni A, Feldman S, et al. Quality of life in patients with psoriasis. Health and Quality of Life Outcomes 2006;4:35.
4. Mitchel RC, Carson RT. Using surveys to value public goods: the contingent valuation method. Washington DC: Resources for the future 1989; 17-49.
5. Carson RT, Hanemann M. Contingent Valuation. In: Mäler K-G, Vincent JR, editors. Netherlands: Elsevier BV; 2005:822-920.
6. Mitchel RC, Carson RT. Using surveys to value public goods: the contingent valuation method. Washington DC: Resources for the future 1989: 88.
7. Arrow K, Solow R, Portney PR, et al. Report of the NOAA panel on contingent valuation. Federal Register 58. 1993, pp. 4601-14.
8. Smith R, Sach T. Contingent Valuation: What needs to be done? Health Economics, Policy and Law 2010;5:91-111.
9. Atanasov N, Dobrev H, Raytcheva R, et al. Contingent valuation of the patients’ willingness to pay for dermatological and dental treatment. Journal of International Scientific Publications: Economy & Business 2013;7(2):219-28.
10. Drummond MF, O’Brien BJ, Stoddart GL, et al. [Methods for the economic evaluation of health care programs.] 2nd ed. Sofia: MF; 2007:289-94 (in Bulgarian).
11. McIntosh E, Clarke PM, Frew EJ, et al, eds. Applied methods of cost-benefit analysis in health care. Oxford: Oxford University Press; 2010:127-38.
12. Edejer TT, Baltussen R, Adam T, et al, editors. Making choices in health: WHO Guide to cost-effectiveness analysis. Geneva: WHO Geneva; 2003:18.
13. Hu SW, Holt EW, Husni ME, et al. Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriatic arthritis: A Pilot Study. Semin Arthritis Rheum 2010;39(5):384-97.
14. Delfino MHE, Holt EW, Taylor CR, et al. Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriasis: A pilot study. J Am Acad Dermatol 2008;59:439-47.
15. Lundberg L, Johannesson M, Silverdahl M, et al. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999;141(6):1067-75.
16. Radtke MA, Schäfer I, Gajur A, et al. Willingness-to-pay and quality of life in patients with vitiligo. Br J Dermatol 2009;161(1):134-9.
17. Horn E, Fox K, Patel V, et al. Association of patient reported psoriasis severity with income and employment. J Am Acad Dermatol 2007;57(6):963-71.